AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15083368 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT with 0.625 mg oestrogen/day and 0.15 mg norgestrel
Number of subjects: 65
Study 15083368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 65
Study 11228385 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine (DTP-Hib-HB) plus placebo (Group A, n=619)
Number of subjects: 2156
Study 11228385 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent vaccine (DTP-HB) plus Hib vaccine (Group B, n=620)
Number of subjects: 2156
Study 11228385 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent vaccine (Hib-HB) plus DTP (Group C, n=226)
Number of subjects: 2156
Study 11228385 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent hepatitis B vaccine at birth followed by pentavalent vaccine (Group E, n=460)
Number of subjects: 2156
Study 11228385 — intervention group
Group type: COMPARATOR
Intervention: Licensed control vaccines (DTP, Hib, HB) (Group D, n=231)
Number of subjects: 2156
Study 9828772 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol (topical and systemic application)
Number of subjects: 24
Study 9828772 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol (topical application)
Number of subjects: 24
Study 9828772 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol (systemic application)
Number of subjects: 24
Study 7666389 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of entertainment films with guidance
Number of subjects: 0
Study 7666389 — intervention group
Group type: EXPERIMENTAL
Intervention: Entertainment films
Number of subjects: 0
Study 2107116 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative gastrostomy (OG)
Number of subjects: 121
Study 2107116 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic gastrostomy (PEG)
Number of subjects: 121
Study 6106098 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (carbohydrate 53%, fibre 54 g)
Number of subjects: 8
Study 6106098 — intervention group
Group type: COMPARATOR
Intervention: Diet A (carbohydrate 53%, fibre 16 g)
Number of subjects: 8
Study 6106098 — intervention group
Group type: COMPARATOR
Intervention: Diet C (carbohydrate 42%, fibre 20 g)
Number of subjects: 8
Study 6106098 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 8
Study 31652771 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Fall training program
Number of subjects: 457
Study 31652771 — intervention group
Group type: COMPARATOR
Intervention: Equilibrium exercises (Control)
Number of subjects: 457
Study 27771172 — intervention group
Group type: EXPERIMENTAL
Intervention: 250mg resveratrol daily for 3 months
Number of subjects: 271
Study 27771172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 24467669 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month supervised exercise programme (32 men)
Number of subjects: 63
Study 24467669 — intervention group
Group type: COMPARATOR
Intervention: Usual care (31 men)
Number of subjects: 63
Study 24297381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg qw
Number of subjects: 306
Study 24297381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg q2w
Number of subjects: 306
Study 24297381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg q2w
Number of subjects: 306
Study 24297381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab ≥150 mg q2w
Number of subjects: 306
Study 24297381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 22421736 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% Knowledge of Results (KR) frequency
Number of subjects: 100
Study 22421736 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Knowledge of Results (KR) frequency
Number of subjects: 100
Study 19131458 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial risk information
Number of subjects: 118
Study 19131458 — intervention group
Group type: COMPARATOR
Intervention: General risk factors alone
Number of subjects: 118
Study 17454714 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive recruitment into telephone counseling
Number of subjects: 0
Study 17454714 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study 14743286 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible and infrared polarized (VIP) light (400‐3400 nm, 95% polarization, 40 mW cm(2), 12 J cm(2))
Number of subjects: 0
Study 14743286 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro irradiated blood
Number of subjects: 0
Study 14743286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of irradiated and non‐irradiated autologous blood 1:10
Number of subjects: 0
Study 14743286 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP light exposure
Number of subjects: 0
Study 11202662 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 20
Study 11202662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9437309 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE/PC‐IOL
Number of subjects: 3400
Study 9437309 — intervention group
Group type: COMPARATOR
Intervention: ICCE‐AG
Number of subjects: 3400
Study 9437309 — intervention group
Group type: COMPARATOR
Intervention: ICCE
Number of subjects: 3400
Study 8124972 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination
Number of subjects: 59
Study 8124972 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 59
Study 12283724 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine instilled paracervically
Number of subjects: 46
Study 12283724 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 46
Study 4531657 — intervention group
Group type: EXPERIMENTAL
Intervention: Male experimenters with expectancy set
Number of subjects: 96
Study 4531657 — intervention group
Group type: EXPERIMENTAL
Intervention: Female experimenters with expectancy set
Number of subjects: 96
Study 4531657 — intervention group
Group type: COMPARATOR
Intervention: Naive experimenters (control group)
Number of subjects: 96
Study 4531657 — intervention group
Group type: COMPARATOR
Intervention: Experimenter sex effects
Number of subjects: 96
Study 4531657 — intervention group
Group type: COMPARATOR
Intervention: Interaction effects of experimenter and subject sex
Number of subjects: 96
Study 30120894 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 638
Study 30120894 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (control)
Number of subjects: 638
Study 29162057 — intervention group
Group type: EXPERIMENTAL
Intervention: Go NAPSACC (intervention group, n=18)
Number of subjects: 33
Study 29162057 — intervention group
Group type: COMPARATOR
Intervention: Delayed access (control group, n=15)
Number of subjects: 33
Study 25947117 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction drain
Number of subjects: 0
Study 25947117 — intervention group
Group type: COMPARATOR
Intervention: Closed passive gravity drain
Number of subjects: 0
Study 23140661 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (100 mg/day)
Number of subjects: 65
Study 23140661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 21257305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital follow-up plus EGP
Number of subjects: 299
Study 21257305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up plus EGP
Number of subjects: 299
Study 21257305 — intervention group
Group type: COMPARATOR
Intervention: Hospital follow-up without EGP
Number of subjects: 299
Study 21257305 — intervention group
Group type: COMPARATOR
Intervention: Telephone follow-up without EGP
Number of subjects: 299
Study 18602331 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable audio-biofeedback system
Number of subjects: 9
Study 18602331 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (eyes closed on solid surface, eyes open on foam cushion surface, eyes closed on foam cushion surface)
Number of subjects: 9
Study 17685467 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX)
Number of subjects: 9
Study 17685467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 14971968 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening performance (6 PM)
Number of subjects: 0
Study 14971968 — intervention group
Group type: COMPARATOR
Intervention: Morning performance (8 AM)
Number of subjects: 0
Study 11720400 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing reflex measured by latent time (LT) for swallowing following bolus injection of distilled water.
Number of subjects: 24
Study 11720400 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing reflex measured by inspiratory suppression time (IST) from swallowing termination to the next onset of inspiration.
Number of subjects: 24
Study 11720400 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing reflex measured by threshold for evoking the swallowing response in terms of a volume of water (TV).
Number of subjects: 24
Study 11720400 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of nocturnal nadir SaO2 with swallowing reflex measures.
Number of subjects: 24
Study 9415000 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized calf skeletal muscle training (unilateral calf plantar flexion exercise)
Number of subjects: 7
Study 8326162 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug combination (metoclopramide, thiethylperazine, diphenhydramine, dexamethasone, diazepam)
Number of subjects: 32
Study 3511346 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 2 mg IV
Number of subjects: 5
Study 3511346 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study 30377185 — intervention group
Group type: EXPERIMENTAL
Intervention: mDiabetes
Number of subjects: 172
Study 30377185 — intervention group
Group type: COMPARATOR
Intervention: pLogbook
Number of subjects: 172
Study 28987804 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 350 μg
Number of subjects: 91
Study 28987804 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 700 μg
Number of subjects: 91
Study 28987804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium 500 μg
Number of subjects: 91
Study 28987804 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 22 μg
Number of subjects: 91
Study 28987804 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg
Number of subjects: 91
Study 28987804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 26560987 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral sustained release morphine daily for 4 days
Number of subjects: 38
Study 26560987 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 days
Number of subjects: 38
Study 24317352 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital 'plasma-first' resuscitation
Number of subjects: 0
Study 24317352 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma delivered early in the emergency department
Number of subjects: 0
Study 23158425 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural space preloaded with epinephrine (1:200 000)
Number of subjects: 100
Study 23158425 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 100
Study 20018804 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 5% C(4) sugars
Number of subjects: 5
Study 20018804 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 16% C(4) sugars
Number of subjects: 5
Study 20018804 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 32% C(4) sugars
Number of subjects: 5
Study 16615036 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine adjunctive therapy
Number of subjects: 0
Study 16615036 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostics for confounding in PK/PD models
Number of subjects: 0
Study 16086046 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (2 g/m²/dose, maximum 4 g, twice daily until 28 days post transplant)
Number of subjects: 120
Study 16086046 — intervention group
Group type: COMPARATOR
Intervention: Glycine (control group)
Number of subjects: 120
Study 11897246 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA 1.5 g
Number of subjects: 16
Study 11897246 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA 3.0 g
Number of subjects: 16
Study 11897246 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA 6.0 g
Number of subjects: 16
Study 11897246 — intervention group
Group type: COMPARATOR
Intervention: BCAA (middle-dose group)
Number of subjects: 16
Study 11897246 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (1.5 and 3.0 g)
Number of subjects: 16
Study 10451133 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral 3-in-1 block with 40 ml ropivacaine 0.2% and 20 ml ropivacaine 0.2% infiltration at the end of surgery
Number of subjects: 44
Study 10451133 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 44
Study 7587906 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26 plus CCNU
Number of subjects: 34
Study 7587906 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy protocol without VM-26 and CCNU
Number of subjects: 34
Study 2112489 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide acetate depot, 3.75 mg intramuscularly every 28 days for four injections (n = 10)
Number of subjects: 20
Study 2112489 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 10)
Number of subjects: 20
Study 2112489 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Number of subjects: 20
Study 110027 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium chromoglycate (DSCG) nasal spray (2%)
Number of subjects: 38
Study 110027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31112399 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (155-195 U)
Number of subjects: 1384
Study 31112399 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1384
Study 27466231 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 501
Number of subjects: 203
Study 27466231 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (USA)
Number of subjects: 203
Study 27466231 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (EU)
Number of subjects: 203
Study 25445827 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based peer coaching for parents (median, 18 calls)
Number of subjects: 948
Study 25445827 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based peer coaching for parents (median, 18 calls) in Medicaid subgroup
Number of subjects: 948
Study 23709432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 12 mg in 100 mL of 0.9% saline administered intravenously for 30 minutes prior to coronary angiography
Number of subjects: 166
Study 23709432 — intervention group
Group type: COMPARATOR
Intervention: Control group received saline only
Number of subjects: 166
Study 23709432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil group
Number of subjects: 166
Study 23709432 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study 21849080 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-4 ml/kg BW/h 0.9% saline intravenously for 6 hours
Number of subjects: 1200
Study 21849080 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment consisting of unrestricted oral fluid intake
Number of subjects: 1200
Study 20110017 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 1-mg + Metformin 500-mg combination tablet (test)
Number of subjects: 30
Study 20110017 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 2-mg + Metformin 500-mg combination tablet (reference)
Number of subjects: 30
Study 16882276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30-45 mg daily for 26 weeks)
Number of subjects: 54
Study 16882276 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone withdrawal (after 26 weeks)
Number of subjects: 54
Study 14742333 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior anaesthetists (group A, >15 years experience)
Number of subjects: 300
Study 14742333 — intervention group
Group type: COMPARATOR
Intervention: Junior anaesthetists (group B, >6 months but <1 year training)
Number of subjects: 300
Study 14742333 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of difficulty score
Number of subjects: 300
Study 11598361 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal hydrolaparoscopy (THL)
Number of subjects: 43
Study 11598361 — intervention group
Group type: COMPARATOR
Intervention: Chromolaparoscopy
Number of subjects: 43
Study 9144049 — intervention group
Group type: EXPERIMENTAL
Intervention: Hapika Powerbrush
Number of subjects: 66
Study 9144049 — intervention group
Group type: COMPARATOR
Intervention: Interplak ultra 10 tuft
Number of subjects: 66
Study 8181411 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to self-selected music during the procedure
Number of subjects: 50
Study 8181411 — intervention group
Group type: COMPARATOR
Intervention: Standard sigmoidoscopy protocol (Control)
Number of subjects: 50
Study 3046984 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of pectin
Number of subjects: 12
Study 3046984 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of pectin
Number of subjects: 12
Study 3046984 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of pectin
Number of subjects: 12
Study 31395087 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence density ratio (IDR)
Number of subjects: 0
Study 31395087 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule of thumb for IDR
Number of subjects: 0
Study 29505900 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) plus Carboplatin (AUC 5) every 3 weeks for four cycles (arm A)
Number of subjects: 402
Study 29505900 — intervention group
Group type: COMPARATOR
Intervention: Oral Uracil-Tegafur (UFT) (250 mg/m2) daily for 2 years (arm B)
Number of subjects: 402
Study 27289007 — intervention group
Group type: EXPERIMENTAL
Intervention: Calories-only labeling
Number of subjects: 643
Study 27289007 — intervention group
Group type: EXPERIMENTAL
Intervention: Calories plus equivalent miles of walking labeling
Number of subjects: 643
Study 27289007 — intervention group
Group type: COMPARATOR
Intervention: No information labeling
Number of subjects: 643
Study 24374004 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Diet (HPD)
Number of subjects: 76
Study 24374004 — intervention group
Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD)
Number of subjects: 76
Study 24374004 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 76
Study 22657157 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/m(2)/wk and prednisone 1 mg/kg/d (maximum 50 mg) for the first 3 months
Number of subjects: 65
Study 22657157 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 65
Study 20491606 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan-based treatment
Number of subjects: 2049
Study 20491606 — intervention group
Group type: COMPARATOR
Intervention: Non-ARB treatment
Number of subjects: 2049
Study 18850395 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceful persuasive messages advocating exercise activities
Number of subjects: 247
Study 18850395 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 247
Study 15006977 — intervention group
Group type: EXPERIMENTAL
Intervention: STRT (stress testing)
Number of subjects: 292
Study 15006977 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocable ischemia (positive STRT results)
Number of subjects: 292
Study 15006977 — intervention group
Group type: EXPERIMENTAL
Intervention: No STRT due to unstable angina
Number of subjects: 292
Study 11691515 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 40 mg
Number of subjects: 8
Study 11691515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11691515 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 8
Study 9176870 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (Sel, N = 12)
Number of subjects: 24
Study 9176870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla, N = 12)
Number of subjects: 24
Study 9176870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Sel and Pla)
Number of subjects: 24
Study 7942642 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy services from an advocate, 4 to 6 hours per week for the first 10 weeks postshelter
Number of subjects: 141
Study 7942642 — intervention group
Group type: COMPARATOR
Intervention: No advocacy services (Control group)
Number of subjects: 141
Study 2906457 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg
Number of subjects: 10
Study 2906457 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg
Number of subjects: 10
Study 2906457 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 300 mg
Number of subjects: 10
Study 2906457 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 600 mg
Number of subjects: 10
Study 2906457 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 29734096 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (bupropion, paroxetine) as adjuncts to mood stabilizers
Number of subjects: 320
Study 29734096 — intervention group
Group type: COMPARATOR
Intervention: Placebo as adjunct to mood stabilizers
Number of subjects: 320
Study 27276373 — intervention group
Group type: EXPERIMENTAL
Intervention: CGT with PLA
Number of subjects: 395
Study 27276373 — intervention group
Group type: EXPERIMENTAL
Intervention: CGT with CIT
Number of subjects: 395
Study 27276373 — intervention group
Group type: COMPARATOR
Intervention: CIT
Number of subjects: 395
Study 27276373 — intervention group
Group type: EXPERIMENTAL
Intervention: CGT
Number of subjects: 395
Study 25199409 — intervention group
Group type: EXPERIMENTAL
Intervention: Diminazene diaceturate (DA) treatment
Number of subjects: 3084
Study 25199409 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded RAP (25%, 50%, and 75% of village herd sprayed)
Number of subjects: 3084